Posts Tagged ‘demonstrates’
Acute Study Demonstrates Safety Of Vertos Medical’s Mild(R) Procedure; Findings Appear In Pain Physician Journal
Medical device company Vertos Medical Inc. has reported that an observational study on mild*, published in the January/February 2010 issue of the peer-reviewed journal Pain Physician, has demonstrated the acute safety of the procedure in the treatment of lumbar spinal stenosis (LSS).1 The study, conducted by leading pain physicians Timothy Deer, M.D…
New Data Presented At ACR Meeting Demonstrates Colcrys(TM) (Colchicine, USP) Significantly Reduces Pain Of Acute Gout Flare Within 24 Hours
URL Pharma, Inc., announced data from a pivotal Phase III study demonstrating that Colcrys(TM) (colchicine, USP), a low-dose colchicine, reduced the pain of gout flares within a 24-hour period as effectively as high-dose colchicine with a side effect profile statistically indistinguishable from placebo. These data and two other Colcrys studies were presented this week at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting in Philadelphia.
Non-Traditional Therapy Is Effective As Pain Management, MU Researcher Demonstrates
More than 30 years ago the United States began embracing the theory, clinical practice and research of ancient Asian medical practices including non-contact therapeutic touch (NCTT). Now, according to a study at the University of Missouri, researchers discovered that 73 percent of patients receiving NCTT experienced a significant reduction in pain, had fewer requests for medication, and slept more comfortably following surgery.
NVIC Says BMJ Review Demonstrates Medical Journal Bias Toward Pharma-Sponsored Influenza Vaccine Studies
In a review of influenza vaccine studies published in the British Medical Journal Tom Jefferson, M.D., Ph.D. (Cochrane Field, Rome, Italy) and colleagues found that published influenza vaccine studies sponsored by industry are treated more favorably by medical journals even when the studies are of poor quality.
First Multiple Dose Clinical Trial Of TorreyPines Therapeutics’ Oral Compound NGX426 Demonstrates Compound Is Safe And Well-Tolerated
TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, was safe and well-tolerated in healthy male and female subjects when dosed once daily for five consecutive days.
Rx Drug Compare
Translator
By N2H